BioNTech SE

Contributing Author

Recent Articles by BioNTech SE

Nov-03	BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update BNTX GlobeNewswire
Oct-26	BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer BNTX GlobeNewswire
Oct-25	BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy BNTX GlobeNewswire
Oct-22	BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer BNTX GlobeNewswire
Oct-20	BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 BNTX GlobeNewswire
Oct-19	BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 BNTX GlobeNewswire
Oct-13	BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer BNTX -7.13% GlobeNewswire
Sep-14	BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients BNTX GlobeNewswire
Aug-27	Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine BNTX BNTX -8.37% GlobeNewswire
Aug-20	BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 BNTX GlobeNewswire
Aug-04	BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update BNTX GlobeNewswire
Aug-03	BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer BNTX GlobeNewswire
Jul-29	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union BNTX GlobeNewswire
Jul-21	BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026 BNTX GlobeNewswire
May-30	Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial BNTX GlobeNewswire
May-22	BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting BNTX GlobeNewswire
May-15	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 BNTX GlobeNewswire
May-07	BioNTech Announces New ADS Repurchase Program BNTX GlobeNewswire
May-05	BioNTech Announces First Quarter 2026 Financial Results and Corporate Update BNTX GlobeNewswire
Apr-21	BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 BNTX +6.09% GlobeNewswire
Apr-11	BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer BNTX GlobeNewswire
Mar-24	BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer BNTX GlobeNewswire
Mar-10	BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update BNTX -17.88% GlobeNewswire
Mar-10	BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 BNTX -17.88% GlobeNewswire
Feb-24	BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026 BNTX GlobeNewswire
Jan-28	BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer BNTX GlobeNewswire
Jan-12	BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference BNTX GlobeNewswire
Dec-18	BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field BNTX GlobeNewswire
Dec-09	BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer BNTX GlobeNewswire
Dec-06	BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer BNTX GlobeNewswire
Dec-03	BioNTech Achieves Minimum Condition in CureVac Exchange Offer BNTX GlobeNewswire
Nov-26	BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration BNTX GlobeNewswire
Nov-03	BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update BNTX GlobeNewswire
Oct-28	BioNTech to Host Innovation Series R&D Day on November 11, 2025 BNTX GlobeNewswire
Oct-27	BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025 BNTX GlobeNewswire
Oct-22	BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. BNTX GlobeNewswire
Sep-23	BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025 BNTX GlobeNewswire
Sep-08	First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity BNTX -8.71% GlobeNewswire
Aug-27	Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 BNTX GlobeNewswire
Aug-04	BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update BNTX GlobeNewswire
Jul-25	Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union BNTX GlobeNewswire
Jul-21	BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025 BNTX GlobeNewswire
Jul-17	BioNTech Announces Ryan Richardson to Step Down from the Management Board BNTX GlobeNewswire
Jun-12	BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer BNTX GlobeNewswire
Jun-02	BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types BNTX +18.05% GlobeNewswire
May-27	BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting BNTX GlobeNewswire
May-05	BioNTech Announces First Quarter 2025 Financial Results and Corporate Update BNTX GlobeNewswire
May-05	BioNTech Announces Appointment of Ramon Zapata to Management Board as Chief Financial Officer BNTX GlobeNewswire

BioNTech SE

Recent Articles by BioNTech SE

Upgrade your Finviz experience